# ABT-348 as Monotherapy or Combination With Carboplatin or Docetaxel to Treat Advanced Solid Tumors

> **NCT01110486** · PHASE1 · COMPLETED · sponsor: **AbbVie (prior sponsor, Abbott)** · enrollment: 102 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** ABT-348
- **DRUG:** ABT-348 and carboplatin
- **DRUG:** ABT-348 and docetaxel
- **DRUG:** ABT-348
- **DRUG:** ABT-348

## Key facts

- **NCT ID:** NCT01110486
- **Lead sponsor:** AbbVie (prior sponsor, Abbott)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2013-09
- **Final completion:** 2013-09
- **Target enrollment:** 102 (ACTUAL)
- **Last updated:** 2013-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01110486

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01110486, "ABT-348 as Monotherapy or Combination With Carboplatin or Docetaxel to Treat Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01110486. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*